Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Nanobiotix Working with Thomas Jefferson

By Drug Discovery Trends Editor | May 16, 2012

Nanobiotix, a company developing novel cancer nanotherapeutics, and Thomas Jefferson University, one of Philadelphia’s premier medical and health sciences universities, announced that they have entered into a research collaboration to accelerate the development of Nanobiotix’ lead compound NBTXR3 in the US.

Under the terms of the collaboration agreement, Nanobiotix will fund a 2-year preclinical research program, which will be directed by Bo Lu, MD, Professor in the Department of Radiation Oncology at Jefferson and Director of the department’s Division of Molecular Radiation Biology. The goal of the program is to study the therapeutic efficacy of NBTXR3, the lead product of Nanobiotix´ NanoXray pipeline.

NBTXR3, a nanoparticle consisting of hafnium oxide crystals, aims to enhance the local destruction of the tumor mass during radiotherapy. It accumulates in the cancer cells and, upon radiation, emits huge amounts of electrons leading to the formation of free radicals. These, in turn, damage the cancer cells and cause their targeted destruction. As a result, the destructive power of standard radiation therapy is locally and selectively enhanced within the tumor cells.

“For the treatment of cancer, it is important to develop ways that cause tumor cells to be more sensitive to radiation therapy,” said Dr. Bo Lu. “We therefore are very interested in approaches that have the potential to amplify the power of the radiation dose inside the tumor without damaging the surrounding healthy cells.”

“The collaboration is an important strategic step to develop our products,” said Laurent Levy, PhD, CEO and co-founder of Nanobiotix. “Jefferson is a leader in the field of radiation oncology and Bo Lu is internationally renowned for his work in clinical and translational radiation oncology. Therefore, we are very much looking forward to the results of this collaboration, which will also help us expand our network and visibility in the Unites States.”

NBTXR3 has been classified in the EU as class III medical device and is currently being tested in a European Phase 1 trial to establish feasibility and safety of NBTXR3 in patients with soft tissue sarcoma. Preliminary data are expected by the end of 2012. Further clinical trials are in preparation in Europe and in the US, where NBTXR3 is classified as a drug.

Date: May 2, 2012
Source: Nanobiotix


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE